Navigation Links
ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver

arma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the company's website at http://www.viropharma.com .

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. .including those relating to the company's progress of its HCV clinical development program as well as its ability to develop an effective small molecule antiviral treatment for HCV disease. Our actual results could differ materially from those results expressed in, or implied by, these forward-looking statements.. Conducting clinical trials for investigational pharmaceutical products is subject to risks and uncertainties. Further testing such as the ongoing Phase 2 clinical studies of HCV-796 with pegylated interferon, may not support any or all of the statements in this press release. There can be no assurance that ViroPharma's additional HCV studies will yield positive results, or that ViroPharma will be successful in gaining regulatory approval of any of its HCV product candidates. These factors, and other factors, including, but not limited to those described in ViroPharma's quarterly report on Form 10-K for the year ended December 31, 2006 filed with the Securities and Exchange Commission, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements.

CONTACT: Vincent J. Milano, Vice President, Chief Operating Officer, ChiefFinancial Officer and Treasurer, +1-610-321-6225, or William C. Roberts,Senior Director, Corporate Communications, +1-610-321-6288, both ofViroPharma Incorporated

Web site:




Page: 1 2 3 4 5 6

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:8/22/2014)... Aug. 22, 2014   Zacks Equity Research highlights Epizyme ... the Day and Panera (Nasdaq: PNRA - Free Report ) ... provides analysis on Amicus Therapeutics (Nasdaq: FOLD - Free Report ... (Nasdaq: SHPG - Free Report ). Here is ... of the Day : The biotech bull market ...
(Date:8/22/2014)... Research and Markets has announced the addition ... Report 2014" report to their offering. ... 2014 is a professional and in-depth study on the ... a focus on the Chinese situation. The report ... classifications, applications and industry chain structure. The particulate respirators ...
(Date:8/22/2014)... , Cali ., Aug. 22, 2014 ... Papillomavirus Conference shows that a therapy being developed by Hera ... two that cause 70 percent of all cervical cancer. ... blocked the replication of HPV-16, HPV-18 and HPV-11 cells, according ... Broker , Ph.D., who presented the findings at the ...
Breaking Medicine Technology:Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Global and Chinese Particulate Respirators Industry Report 2014 2Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2
... DIEGO, Jan. 31, 2011 Volcano Corporation (Nasdaq: ... of Massachusetts has issued a decision that ruled in ... Inc., and against LightLab Imaging, Inc., on all of ... 11-page decision also rejected LightLab,s request for injunctive relief. ...
... its continuing partnerships with Brazilian public health authorities and ... Mr. Nelson dos Santos as interim vice president of ... nonprofit organization whose mission is to improve the health ... programs that help ensure the quality, safety and benefit ...
Cached Medicine Technology:Massachusetts Court Rules in Favor of Volcano and Against St. Jude Medical Subsidiary in Trade Secrets Case 2New Interim Leadership for USP-Brazil 2
(Date:8/22/2014)... Key West Health & Beauty’s ( http://www.keywesthealthandbeauty.com ... anticipated study results of the 12 best and worst ... accompanying infographic on their website. It appears that the ... impact on the skin and contribute to many unwanted ... asked how they determined the results, founder and skin ...
(Date:8/22/2014)... Medical Oncology (ESMO), the leading pan-European organisation representing ... three outstanding individuals receiving the Society,s esteemed annual ... Bokemeyer, Heikki Joensuu and Peter Boyle on the ... Madrid, Spain. , Carsten Bokemeyer will receive the ... transition of cancer discovery into real benefit at ...
(Date:8/22/2014)... in Sweden provides insight on how the brain processes ... different sources and sides of the body, in order ... are presented in the journal Neuron , show ... various types of sensory information, with specialised functional roles ... the main input structure in the basal ganglia, and ...
(Date:8/22/2014)... Oncology (ESMO), the leading pan-European organisation representing medical ... outstanding individuals receiving the Society,s esteemed annual awards. ... Heikki Joensuu and Peter Boyle on the occasion ... Spain. , Carsten Bokemeyer will receive the ESMO ... of cancer discovery into real benefit at patient ...
(Date:8/22/2014)... air in American cities is getting safer to breathe, ... progress has been made in reducing levels of harmful ... said in a news release. Since 1990, there ... from human sources such as coal-fired plants, a 66 ... in lead, which harms brain development in children. ...
Breaking Medicine News(10 mins):Health News:Key West Health & Beauty Announces The 12 Best & Worst U.S. Cities For Skin Study 2Health News:ESMO honors outstanding oncology professionals 2Health News:ESMO honors outstanding oncology professionals 3Health News:The striatum acts as hub for multisensory integration 2Health News:ESMO honours outstanding oncology professionals 2Health News:ESMO honours outstanding oncology professionals 3Health News:Air in U.S. Cities Getting Cleaner, EPA Says 2
... Consuming Vitamin B ,With the rising costs of healthcare, ... a cheap and effective way of warding off health ... and heart disease//. ,Research in the past ... acid known to be a marker of cardiovascular disease ...
... bald mice to get fur on the body, says a ... C. Thompson and colleagues at Johns Hopkins University School// of ... encodes a protein that is essential for hair follicle regeneration. ... Hairless gene, hair growth is initially normal. But once hair ...
... Sometimes the answers to complex problems lies at hand but ... case with a new anti obesity drug//. A weight control ... monitor body fat content may yield new approaches for treating ... further suggest that particular variants of the protein SH2-B might ...
... is considering whether to temporarily ban the Environmental Protection ... a pesticide should be marketed//. Lawmakers on Capitol Hill ... moratorium on the conduct and use of studies that ... conducted by companies seeking to have their pesticides approved ...
... Manipur have hope at hand with an international aid ... care and treatment//.,The Nobel prize-winning Medicines Sans Frontieres (MSF) ... understanding with the Manipur government to provide healthcare services, ... Dutch chapter of the MSF would be involved in ...
... some people vulnerable to suffer from the dreaded disease ... diagnose the risk//. ,According to the most complete ... the researchers from Vanderbilt University in Nashville, Tennessee at ... in San Diego, a cluster of genes on chromosome ...
Cached Medicine News:Health News:An Answer To Obesity: Weight Control Protein 2Health News:US Senate Votes against Testing of Pesticide on Humans 2Health News:Specialized Clinics For Manipur's AIDS Patients 2
The Olympus continuous flow cystoscope was especially designed for laser treatment of the prostate and for collagen injection....
... Prostatron® System uses Cooled ... -TUMT®) to deliver precisely ... heat and destroy hyperplastic ... unique cooling mechanism simultaneously ...
... provides diagnostic testing in an easily ... a PCMCIA card,providing you diagnostic testing ... full-featured and performs all the,measurements performed ... to Office,Medic software for real-time data ...
... is a simple "1, 2, 3 ... compact with a streamline design It ... 13.5 lbs. It rapidly charges to ... full summary pre- & post-event documentation ...
Medicine Products: